8-K: Venus Concept Reports Q3 2024 Results: Revenue Misses Expectations, Debt Reduced

Venus Concept's third-quarter revenue fell short of estimates, but the company made progress in reducing debt and operational costs.

Summary

• Venus Concept announced its financial results for the third quarter of 2024, revealing a 15% year-over-year decrease in total revenue to $15.0 million, falling below the expected $17.0 million.
• The company's operating expenses decreased by 10% year-over-year, which helped limit the GAAP operating loss to 6% despite the revenue decline.
• Adjusted EBITDA loss for the quarter was $5.9 million, compared to a $4.6 million loss in the same period last year.
• Cash used in operations for the first nine months of 2024 was $7.3 million, a 40% reduction compared to the previous year.
• The company successfully reduced its total debt obligations by 54% from $74.9 million at the end of 2023 to $34.6 million as of September 30, 2024.
• Venus Concept received regulatory clearances in Canada and Australia for its Venus Bliss MAX system.
• The company expects revenue of at least $17.0 million for the fourth quarter of 2024, representing a 6% year-over-year decline but a 13% increase quarter-over-quarter.

Sentiment

Score: 4

Explanation: The document presents mixed results with a revenue miss and increased EBITDA loss, but also highlights positive progress in debt reduction and cost control. The overall sentiment is cautiously negative due to the financial underperformance.

Positives

• Cash used in operations decreased by 40% year-over-year for the first nine months of 2024, indicating improved cash flow management.
• Total debt obligations were significantly reduced by 54% since the end of 2023.
• Operating expenses decreased by 10% year-over-year, showing progress in cost control.
• The company secured regulatory approvals for its Venus Bliss MAX system in Canada and Australia, expanding its market reach.
• The company expects a 13% increase in revenue quarter-over-quarter for the fourth quarter of 2024.

Negatives

• Third-quarter revenue decreased by 15% year-over-year and missed the company's estimate of at least $17.0 million.
• Adjusted EBITDA loss increased to $5.9 million from $4.6 million in the same quarter last year.
• Gross profit decreased by 19% year-over-year, primarily due to tighter third-party lending practices and decreased international revenue.
• The company experienced a 23% decrease in revenue in the United States.
• The percentage of total systems revenue derived from internal lease programs decreased from 31% to 23% year-over-year.

Risks

• Macroeconomic headwinds, particularly in the US, continue to challenge aesthetic capital equipment sales.
• Tighter third-party lending practices are negatively impacting capital equipment sales.
• The company is experiencing a decrease in revenue from its internal lease programs.
• The company is facing a challenge from the Canada Revenue Agency regarding a denial of CEWS claims from 2020-2021.
• The company's future performance is subject to risks and uncertainties described in their SEC filings.

Future Outlook

The company expects total revenue for the three months ending December 31, 2024, to be at least $17.0 million, representing a 6% year-over-year decline but a 13% increase quarter-over-quarter.

Management Comments

• Third quarter revenue results were softer than the expectations we outlined during our second quarter report.
• Aesthetic capital equipment sales continue to be challenged by macroeconomic headwinds particularly in the US, as expected.
• We continue to see evidence that our efforts to reposition the business over the last eighteen months have been proving successful.
• We are enhancing our cash flow profile and remain focused on enhancing the health of our balance sheet and the Company's foundation to support long-term, sustainable, profitability and growth in the future.

Industry Context

The medical aesthetics industry is facing macroeconomic challenges, particularly in the US, which is impacting capital equipment sales. Venus Concept's results reflect these broader industry trends, with the company focusing on cost control and debt reduction to navigate the current environment.

Comparison to Industry Standards

• While specific competitor data isn't provided in this document, the 15% revenue decline and increased EBITDA loss suggest Venus Concept is facing challenges similar to other companies in the medical aesthetics sector that are experiencing macroeconomic headwinds.
• The company's focus on reducing debt and operating expenses aligns with industry best practices for companies facing revenue pressures.
• The regulatory approvals for Venus Bliss MAX in Canada and Australia are positive steps for market expansion, which is a key strategy for growth in the medical device industry.
• The company's internal lease program revenue decline is a concern, as it indicates a potential shift in customer preferences or competitive pressures in financing options.

Legal Proceedings

• The Canada Revenue Agency (CRA) has assessed a denial of CEWS claims made by the Company in 2020 and is requesting repayment of $418. The Company disputes the CRA assessment and intends to challenge this matter.

Related Party Transactions

• The company exchanged $15.0 million of its senior debt held by affiliates of Madryn Asset Management, LP for shares of its Series Y preferred stock.

Stakeholder Impact

• Shareholders may be concerned about the revenue miss and increased EBITDA loss.
• Employees may be affected by the restructuring activities designed to improve the company's operations and cost structure.
• Customers may benefit from the company's new product launches and regulatory approvals.
• Creditors may be reassured by the company's debt reduction efforts.

Next Steps

• The company will continue to execute its transformation plan.
• Management will host a conference call to discuss the results.
• The company will focus on enhancing its cash flow profile and balance sheet.
• The company will continue to implement its turnaround plans, including debt restructurings and financings.

Key Dates

Keywords

Venus Concept, medical aesthetics, financial results, revenue, EBITDA, debt reduction, operating expenses, Venus Bliss MAX, regulatory approvals, capital equipment